What to Expect
Inform patients that they may experience adverse reactions after receiving SHINGRIX. In clinical trials, the most common adverse reactions observed were pain, redness, and swelling at the injection site, myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms.1
Because each patient’s clinical situation is unique, GSK has no specific recommendations on adverse reaction management. GSK recommends healthcare professionals use their clinical judgment. Specific management of adverse reactions was not studied in the clinical trials of SHINGRIX.
Explain to patients that the efficacy results of SHINGRIX were demonstrated in clinical trials when administered as a 2-dose series. That is why it is important that your patients receive both doses of SHINGRIX.1
To help ensure series completion, encourage your patients to schedule their second dose for anytime between 2 and 6 months after their first dose.
Topics to Discuss with Your Patients
Inform patients of the potential benefits and risks of immunization with SHINGRIX.
- *Data from the phase 3 ZOE-50 (≥50 years of age) trial and pooled data in individuals ≥70 years of age from the phase 3 ZOE-50 and ZOE-70 trials from subjects who received 2 doses of SHINGRIX (N=7344 and 8250, respectively) or placebo (N=7415 and 8346, respectively) and did not develop a confirmed case of herpes zoster within 1 month after the second dose. See study designs on Efficacy page for more details.1
You may also be interested in:
Watch a range of informative videos including highlights of pivotal trials, MOA and reconstitution videos.